Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study

Completed 400 enrolled Nanjing First Hospital, Nanjing Medical University

RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy and safety of Tegoprazan-amoxicillin dual therapy and bismuth quadruple therapy based on furazolidone in the treatment of Helicobacter pylori eradication, the eradication rate, patient compliance, and adverse drug reactions of H. pylori infection were compared in a multi-center clinical joint study in Jiangsu Province.

Timeline

Start: 2024-03-31
Primary completion: 2025-09-01
Completion: 2025-09-10

Outcome

Met primary endpoint

paper Non-inferiority of the TA regimen was established (P = 0.006). PMID 42457948 ↗

Publications

Wang H, Qu Y, Wang J, Yao J, Yang Z, Shen L, Ye X, Fei C, Xi M, Xu M, Ge J, Zhang Z, Zhang Z. Tegoprazan-based dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a prospective, multicenter, open-label, non-inferiority, randomized controlled trial. Sci Rep. 2026 Jul 15. doi: 10.1038/s41598-026-62237-4. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amoxicillin	Other / unclassified	1000 mg	Oral
Subject	Colloidal pectin bismuth	Unknown	300 mg	Oral
Subject	Furazolidone	Small molecule	100 mg	Oral
Background	Tegoprazan	Other / unclassified	50 mg	Oral